Jesse L. Goodman, MD, MPH

Medical Degree:Albert Einstein College of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: University of California, Los Angeles

Jesse Goodman, M.D., M.P.H., is a Professor of Medicine and directs Georgetown’s Center on Medical Product Access, Safety and Stewardship (COMPASS) which focuses on informing science based policy to address public health needs, including emerging infections and antimicrobial resistance.

He is an Attending Physician in Infectious Diseases at Georgetown University, Washington DC Veteran’s Administration and Walter Reed National Military Medical Centers. He also is a faculty member in the Georgetown Global Infectious Disease program and Senior Scholar with the O’Neill Institute for National and Global Health Law. He previously was the Chief Scientist and Deputy Commissioner for Medicine and Public Health of the U.S. Food and Drug Administration (FDA), also serving as part of the US government’s senior leadership for major public health responses, including the 2009 H1N1 pandemic. Prior to being FDA Chief Scientist, he directed FDA’s Center for Biologics Evaluation and Research and before that served as Senior Advisor to the FDA Commissioner and co-chaired the U.S. Task Force to Combat Antimicrobial Resistance. Prior to his government service, he was Professor and Chief of Infectious Diseases at the University of Minnesota, where his laboratory first isolated and characterized Anaplasma phagocytophilum, the causative agent of the tick-borne disease human granulocytic anaplasmosis and used molecular tools to characterize B. burgdorferi infections of humans, and where he led studies on treatment and prevention of infections in immunocompromised hosts.

He has served on a variety of CDC, NIH, DOD, CEPI and WHO Advisory Committees, helping author the Global Vaccine Action Plan, and is currently on CDC’s Board of Scientific Counselors, DC Health’s Healthcare Acquired Infection Advisory Board, and a scientific advisor to the International Aids Vaccine Initiative (IAVI). He is past president of the US Pharmacopeia (USP), a voluntary standards organization devoted to global medicines quality. He serves on the boards of USP, of GSK, chairing its Science Committee, and of Intellia Therapeutics, which is pioneering CRISPR based medicines. He trained in Infectious Diseases and Hematology/Oncology at UCLA and has been elected to the American Society for Clinical Investigation and the National Academy of Medicine where he is a member of the Forum on Microbial Threats.